Saltar al contenido
Merck

Helicobacter pylori antimicrobial resistance rates in the central region of Portugal.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases (2014-06-04)
N Almeida, J M Romãozinho, M M Donato, C Luxo, O Cardoso, M A Cipriano, C Marinho, A Fernandes, C Calhau, C Sofia
RESUMEN

Helicobacter pylori resistance to antimicrobial agents is steadily increasing. It is extremely important to be aware of the local prevalence of antibiotic resistance so as to adjust treatment strategies. During this single-centre, prospective study, we aimed to determine primary and secondary resistance rates of H. pylori to antibiotics as well as host and bacterial factors associated with this problem. Overall, 180 patients (131 female; mean age 43.4±13.5 years; primary resistance 103; secondary resistance 77) with positive (13) C-urea breath test were submitted to upper endoscopy with gastric biopsies. Helicobacter pylori was cultured and antimicrobial susceptibility was determined by Etest and molecular methods. Clinical and microbiological characteristics associated with resistance were evaluated by logistic regression analysis. Among the 180 isolates 50% were resistant to clarithromycin (primary 21.4%; secondary 88.3%), 34.4% to metronidazole (primary 29.1%; secondary 41.6%), 33.9% to levofloxacin (primary 26.2%; secondary 44.2%), 0.6% to tetracycline and 0.6% to amoxicillin. Being female was an independent predictor of resistance to clarithromycin and metronidazole. Previous, failed, eradication treatments were also associated with a decrease in susceptibility to clarithromycin. History of frequent infections, first-degree relatives with gastric carcinoma and low education levels determined increased resistance to levofloxacin. Mutations in the 23S rRNA and gyrA genes were frequently found in isolates with resistance to clarithromycin and levofloxacin, respectively. This study revealed that resistance rates to clarithromycin, metronidazole and levofloxacin are very high and may compromise H. pylori eradication with first-line and second-line empiric triple treatments in Portugal.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Amoxicillin, 95.0-102.0% anhydrous basis
Sigma-Aldrich
Metronidazole, BioXtra
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
Tetracycline, 98.0-102.0% (HPLC)
Sigma-Aldrich
Clarithromycin, ≥95% (HPLC)
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
USP
Amoxicillin T trihydrate, United States Pharmacopeia (USP) Reference Standard
Supelco
Metronidazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Clarithromycin, 96.0-102.0% (HPLC)
Supelco
Metronidazole, analytical standard
Supelco
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Clarithromycin, United States Pharmacopeia (USP) Reference Standard
USP
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Supelco
Levofloxacin, analytical standard
Supelco
Metronidazole, VETRANAL®, analytical standard
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Metronidazole, European Pharmacopoeia (EP) Reference Standard
Clarithromycin, European Pharmacopoeia (EP) Reference Standard